Scientists create mouse model of melanoma that generates hope for the use of targeted therapies

March 13, 2009

Researchers have developed a new mouse model that allows them to replicate normal pigment cells at the earliest stages of conversion to malignant skin cancer in humans. After testing the mouse with a combination of two drug therapies, the team found the treatment caused a statistically significant regression in cancer cell development.

The study was led by scientists at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and the University of Vermont College of Medicine. The findings are published today (March 12, 2009) in the advance online edition of "Nature Genetics."

Melanoma is a type of skin cancer that develops from pigment cells called melanocytes. It is the most rapidly increasing cancer in the United States, according to the National Cancer Institute, with more than 62,000 people diagnosed with the disease in 2008. Of these, it is estimated that more than 8,000 will die within three to four years after a form of the recurrent disease spreads, or metastasizes, to other sites in the body.

"There has not been a major advance in the treatment of metastatic melanoma in the last 25 years," says Martin McMahon, PhD, senior co-author of the study and Efim Guzik Distinguished Professor in Cancer Biology at the UCSF. "While other cancers are more common, it is the rate of increase and the often aggressive course of the disease that worries people who study melanoma."

By far the earliest and most common genetic alteration in melanoma is a mutation in an oncogene-a gene that can cause normal cells to become cancer cells-called BRAF. For this study, scientists generated a mouse that allowed them to switch on that oncogene in melanocytes. The research team found that the benign lesions observed in a mouse expressing the gene are very similar to the benign sun-induced moles that often develop in humans and which also contain BRAF mutations. Benign sun-induced moles generally never progress to malignancy, but such lesions are a potential precursor to cancer.

BRAF mutation is not the only genetic alteration observed in human melanoma. It is often found in combination with the silencing of PTEN, an important tumor-suppressor gene. By combining activation of the BRAF gene with deletion of the PTEN suppressor gene, the research team effectively modeled a combination of mutations seen in about 30 percent of all malignant melanomas. Under these circumstances the mice rapidly developed melanoma that displayed extensive metastasis.

Next, the researchers studied the impact of a combination of two different drugs on mouse melanoma. Each drug in its own unique way targeted the internal growth control circuits of cancer cells. One drug is an experimental therapy supplied by Pfizer Inc., that inhibits the action of a protein called MEK that acts "directly downstream of BRAF," McMahon explained. Consequently, oncogenic BRAF gene generates a series of signals that support a high level of MEK activity. The other drug, Rapamycin, is an immunosuppressant drug already in clinical trials for cancer. As single agents, these drugs could prevent the onset of melanoma but, more importantly, when administered in combination to mice with pre-existing melanoma, there was a modest but statistically important level of regression in cancerous cells, according to McMahon.

"The study indicates that the mouse model we have built, based on the cardinal genetic features of the human disease, can be used to test responses to targeted therapeutics," says McMahon. "The signal failure to improve the prognosis of metastatic melanoma patients is likely to be improved on in years to come by the use of agents that target specific genetic mutations in the disease. Nevertheless I believe it will up be three to five years before the types of pre-clinical experiments we are doing right now will result in improved prognosis for patients with metastatic melanoma."

The scientists emphasized that although they engineered mice with very specific genetic alterations, it is possible that human melanoma is genetically more complex than the model they have generated. To address this, McMahon and Boris Bastian, MD, professor of dermatology and clinical professor of pathology at UCSF, are discussing the possibility of making additional modifications to the mouse model to make it more relevant to the genetic complexity found in human melanoma.

"Although the combination of drugs we administered might not be used in the clinic, our work suggests further avenues of research in a pre-clinical setting and in clinical trials," says McMahon. "In fact it is fair to say also that there are a number of drugs already in clinical trials that target the same pathways we are interested in."

The work was an integral collaboration between McMahon's laboratory at UCSF and the laboratory of Marcus Bosenberg, MD, PhD at the University of Vermont. Bosenberg is a senior co-author with McMahon. The studies at the University of Vermont were primarily conducted by David P. Curley, a student in the laboratory of Bosenberg. The work at UCSF was primarily carried out by a post-doctoral fellow, David Dankort, PhD, who has since become a faculty member at McGill University in Montreal.

Additional co-authors of the paper were Robert A. Cartlidge and Anthony N. Kamezis of the UCSF Helen Diller Family Comprehensive Cancer Center, Betsy Nelson and William E. Damsky, Jr., of the University of Vermont College of Medicine, and Mingjian J. You and Ronald A. DePinho of the Dana-Farber Cancer Institute and Harvard Medical School.

The study was supported by the Diana Ashby Award of The Melanoma Research Foundation, which was presented to McMahon, a UC Discovery grant in partnership with Genentech, Inc., and the National Institutes of Health.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

The University of California, San Francisco

Beating Melanoma: A Five-Step Survival Guide (A Johns Hopkins Press Health Book)
by Steven Q. Wang (Author)

Dr. Steven Q. Wang, a world-renowned skin cancer expert, provides an essential guide for people with melanoma and their families. The book’s unique, practical format approaches the disease in two phases, just as people with melanoma need to do. First comes a step-by-step guide for what Dr. Wang calls the "mad rush" phase—an intense and stressful period from diagnosis to completing initial treatment. Dr. Wang's calm guidance helps readers through this critical time, using an easy to understand plan for ensuring optimal treatment and survival outcomes. Once the mad rush phase is over, the "marathon phase" begins—life resumes its normal shape but with lingering concerns about new melanoma and metastases. Here Dr. Wang addresses common questions about prevention and prognosis. Beating...

A Melanoma Patient's Survival Guide: Lemons Really Do Make Lemonade: You Just Have to Add a Little Sugar
by Sally Welsh (Author)

A Melanoma Patient’s Survival guide: Lemons Really Do Make Lemonade is an effort to bring awareness to the subject of melanoma. This insidious disease is being diagnosed in over 50,000 people a year in the United States alone. Melanoma will affect one in seventy-five people in California. That rate goes up each year. Melanoma can be a silent killer. This heart-warming book was written by a survivor of serious melanoma, Sally Welsh. Sally has shared her experience with thousands of people, and has prepared this book with the hope of making your journey a little easier. Her suggestions deal first of all with the questions you need to ask your doctor, before he cuts into you. You need to know about his initial scanning of you, whether he plans to use a “punch” biopsy or a “scrape”...

Melanoma: Prevention, Detection, and Treatment; Second Edition (Yale University Press Health & Wellness)
by Catherine M. Poole (Author), IV DuPont Guerry (Author)

The incidence of melanoma has increased by 2000% since 1930, and one person dies each hour from the disease. This cutting-edge guide provides scientifically accurate information patients and their families need in order to understand melanoma and its treatment and to receive vital reassurance. It is also a resource for those who want information about preventing the disease or finding it early when it is most curable.
Catherine M. Poole, a melanoma survivor and melanoma patient advocate for many national organizations, and Dr. DuPont Guerry, an internationally renowned melanoma expert, have collaborated to provide current, correct, and easily understood information on the disease. The authors have had first hand contact with a multitude of patients with melanoma, and they understand...

What You Really Need to Know about Moles and Melanoma (A Johns Hopkins Press Health Book)
by Jill R. Schofield (Author), William A. Robinson (Author)

Throughout the world, the incidence of malignant melanoma is increasing at an alarming rate. This dramatic rise is largely due to more frequent and prolonged exposure to intense sun, the result of major changes in clothing styles, recreation, and lifestyle (including widespread access to midwinter resort vacations). Significantly, recent scientific studies have shown an increased number of moles on, and a higher rate of melanoma in, people with the greatest sunscreen use, pointing out the mistaken belief that using sunscreen means getting a "safe" tan. The truth is that most sunscreen provides protection from UVB rays—the rays that cause the sunburn you see and feel—but not from UVA rays—the cancer-causing rays that penetrate deeper into the skin.In this book, physicians Jill R....

The Melanoma Book : A Complete Guide to Prevention and Treatment, Including the Early DetectionSelf-Exam Body Map
by Howard L. Kaufman (Author)

From the founder and Co-Director of the renowned Columbia University Melanoma Center, the first comprehensive guide to help you prevent—and survive—a diagnosis of melanoma. The fastest rising form of cancer worldwide, melanoma can strike at any age. Although rates of cure are higher than they used to be, experts often disagree about the best course of treatment and patients face a bewildering array of possibilities—often with precious little time to choose. Drawing on his years as one of the nation’s foremost researchers and specialists in the field of melanoma treatment, Dr. Howard L. Kaufman shares his easy- to-follow, whole-life plan for detecting melanoma early, making informed decisions after a diagnosis, and taking an active role in treatment.

QuickFACTS Melanoma Skin Cancer: What You Need to Know-NOW
by American Cancer Society (Author)

This pocket-sized reference covers everything from the risk factors of melanoma skin cancer to the diagnosis procedure to living well after treatment. With greater public awareness, early detection of melanoma skin cancer is on the rise and mortality rates are declining; this medical guide emphasizes that all patients should be well-informed decision makers in planning their own treatment and is updated with the latest patient treatment guidelines. An advanced dictionary of cancer-related terms and a list of critical questions to ask health care administrators are also included.

From Melanocytes to Melanoma: The Progression to Malignancy
by Vincent J. Hearing (Editor), Stanley P. L. Leong (Editor)

Leading researchers and clinicians join forces to explain how malignant melanoma develops from its benign precursor cell type. The authors focus on the molecular mechanisms involved in melanogenesis, in the malignant transformation of melanocytes, and in the further progression of primary melanomas into invasive and metastatic melanomas. They also review recent advances in our understanding of the basic biology of melanocytes and the development, migration, and differentiation of melanoblasts into melanocytes. The book provides an up-to-date understanding of the progressive mechanisms of oncological development in malignant melanoma, a likely model of malignant progress for other types of cancer, and the ongoing development of novel therapeutics.

Unforeseen Consequences: A Physician's Personal Triumph Over Advanced Melanoma
by Nicholas Steiner (Author)

Dr. Nicholas Steiner is a Park Avenue internist in his mid-forties. He has a successful medical practice, a stable marriage with a home in the suburbs and enjoys good health. But when he develops melanoma, a potentially fatal type of cancer, everything ch

Malignant Melanoma: Your Way Forward
by Abaco Publishing

You will never cure anything if you don’t do something about the underlying cause. This applies to every illness including malignant melanoma. In my book ‘Malignant Melanoma – Your way Forward’ I explain why it may have developed, giving you something to do to change the underlying causes and bring things under control. It could be related to a vaccination, being burned in the sun, associated with bad eating habits, a poor immune system, infections, too many antibiotics, toxic chemicals, geopathic stress and certainly stresses of everyday life affecting your emotions. When cancer declares itself, it could have been developing for ten or fifteen years. All of this is explained to you in detail as though you are with me in my consulting room. I then give ideas on how to change your...

What You Need To Know About: Melanoma and Other Skin Cancers

This booklet is for people diagnosed with the most common types of skin cancer like Melanoma, Basal cell skin cancer and Squamous cell skin cancer.

Skin cancer is the most common type of cancer in the United States. Each year, more than 68,000 Americans are diagnosed with melanoma, and another 48,000 are diagnosed with an early form of the disease that involves only the top layer of skin. Also, more than 2 million people are treated for basal cell or squamous cell skin cancer each year. Basal cell skin cancer is several times more common than squamous cell skin cancer. Learning about medical care for skin cancer can help you take an active part in making choices about your care.

This booklet tells about, diagnosis and staging, treatment, follow-up care, how to...